Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study (Q28257337)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
scientific article

    Statements

    Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study (English)
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    Henrik Fredriksen
    0 references
    James Wooldridge
    0 references
    Mimi Flensburg
    0 references
    Jørgen Petersen
    0 references
    1 February 2008
    0 references
    0 references
    111
    0 references
    3
    0 references
    1094-100
    0 references

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit